Switzerland Puts Legal Weed to the Test

Filed Under: Warnings on Trial

---

Switzerland kept national prohibition, then built controlled cannabis pilots to test the fears prohibition keeps selling.

Switzerland gave regular cannabis consumers something prohibition has long warned against: a legal, regulated supply.

Then researchers watched what happened.

In fresh results released Sept. 7, the SCRIPT cannabis pilot in Bern, Biel and Lucerne found no sign that pharmacy access increased how often participants used cannabis. The six-month interim report also found movement away from smoking-only use and toward potentially lower-risk methods such as vaporization, oral products or mixed use. The program did not hand cannabis to non-users. Participants were adults who already used cannabis regularly before they entered the trial.

The disaster did not arrive on schedule.

That does not make the findings a legalization victory lap. SCRIPT is not a national retail market, not a commercial dispensary system, and not a youth-use study. It is a randomized controlled pilot built around regulated, not-for-profit cannabis sales through pharmacies, paired with advice from trained pharmacy staff. Switzerland did not simply legalize cannabis and hope for the best. It kept prohibition in place, carved out scientific exceptions, and forced the old warnings into a supervised test.

The results now create a problem for the politics of fear.

Switzerland’s current law remains narrow. Cannabis with 1 percent THC or more is generally prohibited outside authorized exceptions, according to the Swiss Federal Office of Public Health. Adult cannabis use can draw a CHF 100 fixed penalty, while possession of up to 10 grams for personal use is not treated as a criminal offence. Low-THC cannabis below the 1 percent threshold sits in a different category. Medical cannabis has followed a separate path since Aug. 1, 2022, when Switzerland removed the medical-use prohibition and moved cannabis for medical purposes into regular controlled-substance rules, according to Swissmedic.

Non-medical cannabis remains illegal for the country at large. Inside the pilots, approved adult participants may legally buy controlled cannabis under rules Switzerland designed to produce evidence.

That legal split is the point. The Swiss government did not claim prohibition was working perfectly. FOPH says growing, importing, producing and selling cannabis remain prohibited, but consumption is widespread, the black market is thriving and user safety is not guaranteed. Parliament created the legal basis for pilot trials, and FOPH built the machinery to turn that political question into evidence through federally authorized cannabis pilot trials.

SCRIPT is one of those tests. The trial began in 2024 and includes 1,177 participants, with 777 in Bern, 261 in Lucerne and 139 in Biel, according to the Bern city release. Participants buy study cannabis from selected pharmacies, including five in Bern, three in Lucerne and one in Biel. The University of Bern and the University of Lucerne conduct the research, while the cities support the project. FOPH has approved an extension that allows study sales to continue until Oct. 31, 2028.

The interim report is not peer-reviewed yet. The authors say the findings were released before journal publication because the study sits at the intersection of science and politics, where decisions are urgent, and values are contested. That warning belongs in the article because it keeps the story honest. Preliminary evidence is still evidence, but it should not be dressed up as final science.

The study design is stricter than the cannabis-war caricature. SCRIPT compares an access group allowed to buy regulated cannabis in pharmacies with a control group that initially continues buying from the illegal market. The access group receives cannabis through a not-for-profit pharmacy model and counseling focused on risk reduction. The product rules are tight: no advertising, plain packaging, 20 percent THC maximum, purchase limits, simulated taxation, and trained pharmacy advice. Participants can buy no more than 2 grams of THC per purchase and 10 grams of THC per month under the study design, according to the SCRIPT interim report.

Switzerland also controls where study cannabis comes from. FOPH says cannabis used in pilot trials must be produced in Switzerland, except in limited circumstances, and cultivation requires an exceptional federal licence. The rules require quality controls, Swiss-origin expectations, organic-production preference, theft protection and traceability. A grower added to an interested-cultivator list does not automatically receive a supply contract or a licence, according to FOPH’s pilot cultivation rules.

Study cannabis cannot simply drift into the street. FOPH’s pilot FAQ says participants may not pass cannabis to others, and public consumption remains prohibited. The point is controlled access, not a free-for-all.

That control makes the results harder to dismiss.

At the start, nearly all SCRIPT participants used cannabis daily or weekly. The group was mostly male, with a reported average age of 34, and the biggest age band was 26 to 35. The study was never designed to answer whether national legalization would cause non-users to begin using cannabis or whether youth use would rise. The report says that directly. SCRIPT cannot measure effects on non-consumers, adolescents, social norms, the illegal market, or criminal enforcement across society with a single randomized controlled trial.

It can test what happened to regular adult consumers placed inside a regulated pharmacy model.

After six months, the report found little change in cannabis-use frequency between the access group and the control group. Its conclusion on that point was blunt: regulated cannabis dispensing through pharmacies had no recognizable influence on consumption frequency.

The pharmacy model worked in one narrow place. At baseline, 78 percent of the access group and 82 percent of the control group reported smoking cannabis only. Six months later, smoking-only use in the access group dropped to 58 percent, while the control group showed only minor change. The access group increased use of non-smoking methods or combined smoking with other forms.

The legal supply did not send frequency upward in SCRIPT’s first six-month results, and the regulated setting appears to have pushed some participants toward less risky ways of consuming.

The pharmacy counter did something the illegal market does not have to do.

---

M O R E F R O M P O T C U L T U R E M A G A Z I N E

---

SCRIPT participants could buy flower, resin, e-liquids, and tinctures. Cannabis flower made up about 65 percent of total sales, while e-liquids for vaporization accounted for about 21 percent. Resin was 11 percent, and tinctures were 3 percent. The product mix still leaned heavily toward flower, but the availability of e-liquids and tinctures gave counseling somewhere to go. Harm reduction is not a slogan when the product menu and the staff advice point in the same direction.

Participants also valued what prohibition cannot provide. The University of Lucerne said participants rated pharmacy sales mostly positively and especially appreciated consistent product quality, transparent cannabinoid information and legal access without contact with the illegal market. Pharmacy staff also reported largely positive experiences with participants, according to the University of Lucerne.

That is not softness. It is evidence of what regulated access can replace.

The illegal market leaves consumers guessing. SCRIPT’s own analysis of illegal-market samples showed why that guesswork has consequences. Participants submitted 127 illegal cannabis samples at the six-month visit. Nine showed irregularities involving synthetic cannabinoids. Among 69 samples where participants estimated THC content, only one estimate matched the measured value, according to the report. Prohibition did not protect those consumers from bad information. It left them with it.

The interim report also keeps the caution visible. Between study start and the six-month visit, the report listed 51 serious adverse events among 45 people across both groups. Most involved hospital interventions, chronic disease treatments, or mental stress, and one event could not yet be ruled out as related to the study intervention. One safety-relevant incident involved unauthorized resale of study products, and the participant was held accountable. The report said no other police-relevant incidents involving participants were known.

Those facts do not wreck the trial. They prevent a cheap victory speech.

A separate Swiss study published online Sept. 5 in Drug and Alcohol Dependence gives the story another layer. The one-year paper examined 374 regular cannabis users with pharmacy-based regulated access. Products were pharmacist-dispensed, capped at 20 percent THC, and limited to 10 grams of THC per month, according to the journal article.

The study found small but statistically significant reductions in depression scores, anxiety scores, and problematic cannabis-use scores. Cannabis-use frequency increased modestly, from an average of 18.7 to 20.1 days per month, while quantity used per consumption day remained essentially unchanged. The proportion of participants above the possible cannabis-use-disorder threshold did not change significantly, moving from 32.7 percent to 28.6 percent with a p-value of .126.

That study does not say legal cannabis improved mental health. The authors warn that the uncontrolled design prevents causal claims. It does say pharmacy-based regulated access was not associated with mental-health deterioration in that group over one year. The average changes moved slightly toward improvement, even while use-days rose.

The two Swiss findings are not identical, and flattening them would be sloppy. SCRIPT’s randomized six-month comparison found no recognizable effect on consumption frequency. The one-year pharmacy-access study found a modest increase in use-days. Different designs can produce different findings: SCRIPT compares groups during a controlled six-month phase, while the one-year paper follows participants inside a pharmacy-access model without a control group.

Taken together, the evidence is more useful than a slogan. Regulated access did not produce the simple upward-harm story prohibition politics often predicts. One study found stable frequency and movement toward lower-risk use. Another found more frequent use without more quantity, paired with small average reductions in anxiety, depression, and problematic-use scores. Both demand restraint. Neither delivers the panic.

Switzerland now has more than one pilot to read. FOPH currently lists eight authorized cannabis pilot projects: CanLeg, Cann-L, La Cannabinothèque, Cannabis Research Zürich, Grashaus Projects, SCRIPT, WeedCare and ZüriCan. The models vary. Some test pharmacies. Others test nonprofit shops or cannabis social clubs. The federal overview says the pilots are meant to compare distribution systems and show which regulatory models consumers and the public accept.

The national evaluation is still developing. FOPH’s existing cross-project evaluation says that, using June 2025 figures, around 10,400 adults were participating in seven ongoing pilots, with available data running up to July 2025. That figure should not be mistaken for a September 2026 count across every active pilot. It still shows Switzerland has moved beyond symbolic reform. The country is building an evidence base across different access models.

The pilot system also lands inside a live legislative debate. The preliminary Cannabis Products Act, or CanPG, is being revised at the federal level. FOPH says the National Council’s health committee wants to realign cannabis policy by giving adults strictly regulated access while keeping public health and youth protection at the center. The draft would regulate cultivation, manufacturing and trade without promoting consumption, and cannabis would remain classified as a narcotic, according to FOPH’s CanPG page.

The Bern release connects the SCRIPT findings to that debate. City officials said the results support the direction of the CanPG draft, which would allow regulated access for adults across Switzerland while strengthening public health and youth protection. That is a political claim from officials, not a scientific conclusion. The timing still gives the study its force. Switzerland asked pilots to produce evidence for regulation, and the evidence is arriving while lawmakers rewrite the rules.

Prohibition defenders have long argued that legal access will normalize cannabis, increase use and worsen public health. Switzerland is testing a narrower version of that claim under conditions designed to keep the commercial market on a leash. The products are controlled. The supply chain is monitored. Advertising is banned. Access runs through trained staff. Prices include a simulated tax. Participants already used cannabis before enrollment.

Even under those limits, opponents do not get the evidence they want. SCRIPT did not show a consumption-frequency jump. The one-year study did not show worsening mental-health measures or rising quantity. The samples from the illegal market exposed misinformation and synthetic-cannabinoid risk. Participants valued product transparency and no longer had to turn to the illicit market for study cannabis.

The old warnings do not vanish. They narrow.

A careful reader should still ask what happens under a national law, with more adults eligible, more supply points, and more pressure from commercial interests. SCRIPT itself warns that it is not built to measure youth initiation, effects on non-consumers, or broad black-market displacement. The pilot also does not answer what happens if regulators loosen the model, allow stronger advertising, or make price competition the dominant goal.

---

---

Those limits protect the article from propaganda. They also expose how weak the old certainty looks.

Switzerland’s own government says prohibition has left widespread use, a thriving black market and no guarantee of consumer safety. The country then tested a strict pharmacy model with adults already using cannabis. The feared surge did not appear in the six-month SCRIPT results. A separate one-year study found modestly higher frequency but no higher quantity and no significant rise above the possible cannabis-use-disorder screening threshold.

The lesson is not that legalization is harmless.

The lesson is that prohibition’s warnings should not keep getting treated as proven facts while controlled access produces evidence in the other direction.

That leaves policymakers with an uncomfortable choice. They can demand evidence before changing cannabis law. Switzerland has done that. They can insist the evidence be cautious, narrow, and public-health centered. Switzerland has done that too. They can refuse to turn early findings into a blank check for commercial cannabis. No serious person should object.

What they cannot do honestly is keep pretending the old model is protecting the public while the government’s own rationale says the black market is thriving and early pilot evidence has not produced the expected disaster.

Switzerland has not ended the cannabis debate. It has made the debate harder for prohibition to fake.

The country put legal weed to the test inside pharmacies, under federal permission, with controlled products and trained staff. The test did not prove cannabis is safe. It did not prove nationwide legalization would have the same results. It did something more useful.

It forced the warnings to show their work.

---

_{^{©2026 Pot Culture Magazine. All rights reserved. This content is the exclusive property of Pot Culture Magazine and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission from the publisher, except for brief quotations in critical reviews.}}

---

F O R T H E C U L T U R E B Y T H E C U L T U R E